Aurobindo Pharma has received tentative approval for the ANDA drug Lamivudine and Zidovudine tablets, 150 mg / 300 mg with combination. Lamivudine and Zidovudine are in the class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs), which help keep the AIDS virus from reproducing. This fixed-dose combination anti-retroviral drug is intended to be used with other antiretroviral agents for the treatment of HIV-1 infection.According to a Aurobindo Pharma release issued to the BSE, the approval will enable the company to participate in President's Emergency Plan for AIDS Relief (PEPFAR) programme. This is one of the popular combination prescribed by doctors around the world and it is one of the largest seller in the ARV (Anti-Retroviral) segment.
